<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Daptomycin: An overview</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Daptomycin: An overview</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Daptomycin: An overview</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Iain J Abbott, MBBS, FRACP, FRCPA</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kelly A Cairns, BPharm</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David C Hooper, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sheldon L Kaplan, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elinor L Baron, MD, DTMH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Mar 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H743373364"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> is a lipopeptide antimicrobial with activity against gram-positive organisms, including antimicrobial-resistant pathogens such as methicillin-resistant <em>Staphylococcus aureus</em> and vancomycin-resistant <em>Enterococcus</em> spp [<a href="#rid1">1,2</a>]. </p><p>Issues related to pharmacokinetic and pharmacodynamic considerations, challenges with susceptibility testing and emergence of resistance, dosing, monitoring, adverse effects, and drug interactions will be reviewed here.</p><p>Details regarding the management of specific clinical syndromes for which <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> may be used are discussed separately: </p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3176.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3165.html" rel="external">"Staphylococcus aureus bacteremia with reduced susceptibility to vancomycin"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3154.html" rel="external">"Infection due to coagulase-negative staphylococci: Treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/114350.html" rel="external">"Nonvertebral osteomyelitis in adults: Treatment"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">"Antimicrobial therapy of left-sided native valve endocarditis"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/3163.html" rel="external">"Treatment of enterococcal infections"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>(See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents"</a>.)</p><p></p><p class="headingAnchor" id="H121961370"><span class="h1">MECHANISM OF ACTION</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a>, a cyclic lipopeptide, is a large anionic molecule; the primary mechanism of action is calcium-dependent depolarization of the gram-positive bacterial cell membrane. The lipophilic tail of the drug binds and inserts itself into the bacterial membrane and then generates an ion-conducting channel that disrupts the functional integrity of the gram-positive membrane, causing release of intracellular potassium, membrane depolarization, and subsequent cell death [<a href="#rid3">3</a>]. </p><p><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> does not appear to require bacterial cell division or active metabolism for bactericidal activity and has been demonstrated to remain highly active against <em>S. aureus</em> in stationary growth phase [<a href="#rid4">4</a>].</p><p class="headingAnchor" id="H615725382"><span class="h1">SPECTRUM OF ACTIVITY</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> has in vitro bactericidal activity against gram-positive bacteria (including some anaerobes); it is not active against gram-negative bacteria. </p><p>The spectrum of activity includes: <em>Staphylococcus</em> spp (including <em>S. aureus</em> and coagulase-negative staphylococci), <em>Enterococcus</em> spp (both <em>Enterococcus faecium</em> and <em>Enterococcus faecalis</em>), <em>Streptococcus pneumoniae</em> (including penicillin-resistant strains), and other viridans-group <em>Streptococcus</em>, beta-hemolytic <em>Streptococcus </em>spp<em> </em>(namely <em>Streptococcus pyogenes</em>, <em>Streptococcus agalactiae,</em> and <em>Streptococcus dysgalactiae</em>), <em>Corynebacterium</em> spp, <em>Leuconostoc</em> spp, <em>Pediococcus</em> spp, and gram-positive anaerobes (including <em>Clostridium</em> spp and <em>Cutibacterium acnes</em>) [<a href="#rid3">3</a>]. </p><p>Some species of coagulase-negative staphylococci are reported to have reduced susceptibility to <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> (including <em>Staphylococcus auricularis</em>, <em>Staphylococcus capitis</em>, <em>Staphylococcus sciuri</em>, and<em> Staphylococcus warneri</em>) [<a href="#rid5">5,6</a>]. </p><p><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> has decreased activity against <em>Listeria monocytogenes</em> and <em>Actinomyces</em> spp. Daptomycin is not active against the rapid-growing <em>Mycobacterium</em> spp, <em>Nocardia</em> spp, or <em>Rhodococcus</em> spp. </p><p class="headingAnchor" id="H992152929"><span class="h1">SUSCEPTIBILITY TESTING</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> susceptibility breakpoints are summarized in the table (<a class="graphic graphic_table graphicRef130617" href="/z/d/graphic/130617.html" rel="external">table 1</a>). </p><p>Laboratory determination of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> susceptibility is complicated by discrepancies between the Clinical Laboratory and Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) [<a href="#rid7">7,8</a>]. </p><p>The CLSI and EUCAST breakpoint for methicillin-resistant <em>S. aureus </em>(MRSA) is 1 mg/L. CLSI breakpoints for <em>E. faecalis</em> and <em>E. faecium</em> are 4 and 8 mg/L, respectively; EUCAST has determined that there is insufficient evidence to support setting clinical breakpoints for <em>Enterococcus</em> spp [<a href="#rid9">9,10</a>].</p><p><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> susceptibility testing requires fixed concentrations of divalent calcium ions (Ca<sup>2+</sup>). The International Organization for Standardization reference broth microdilution method in cation-adjusted Mueller-Hinton broth must be supplemented with Ca<sup>2+</sup> (to a final concentration of 50 mg/L). It is not possible to perform agar dilution and disk diffusion accurately [<a href="#rid3">3</a>]. </p><p>Use of commercial susceptibility testing methods (such as BD Phoenix, MicroScan, and Vitek2) or a gradient strip test (such as Etest) can overestimate the <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> minimum inhibitory concentration (MIC). In addition, commercial methods may be restricted in reporting susceptibility based on the platform’s package insert and will withhold results for important species, such as <em>E. faecium</em>. </p><p>There is considerable variability in the reproducibility of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> MIC measurements. In general, if a daptomycin-nonsusceptible strain is identified, that isolate should undergo additional testing. In addition, to detect emergence of daptomycin resistance, diagnostic laboratories should strongly consider the need for repeat daptomycin susceptibility testing if an isolate (especially <em>Enterococcus</em> spp and MRSA) is isolated repeatedly while on therapy. </p><p><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> susceptibility breakpoints should not be reported for organisms isolated from the respiratory tract. </p><p class="headingAnchor" id="H3065821717"><span class="h1">RESISTANCE</span><span class="headingEndMark"> — </span>The mechanisms of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> resistance are multifactorial and not fully understood. In general, the changes appear to be isolate-specific, with alterations to the cell membrane and cell wall via adaptions in metabolic function and stress response regulatory pathways. Emergence of resistance appears to occur more commonly in the setting of recalcitrant, deep-seated infections and infections associated with a high organism burden (such as endocarditis, catheter-related bacteremia, or an undrained abscess). </p><p>In <em>S. aureus</em>, there is an association between membrane remodeling and cross-resistance between <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a>, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> (a glycopeptide antimicrobial), and <a class="drug drug_general" data-topicid="95502" href="/z/d/drug information/95502.html" rel="external">dalbavancin</a> (a lipoglycopeptide antimicrobial) [<a href="#rid11">11</a>]. Daptomycin nonsusceptibility has also been observed in some vancomycin-intermediate <em>S. aureus</em> strains [<a href="#rid12">12,13</a>]. Vancomycin resistance in <em>S. aureus</em> strains, which is mediated by the <em>vanA</em> gene, does not affect daptomycin susceptibility. Not all <em>S. aureus</em> strains appear to respond to daptomycin exposure in the same way. There are seemingly conflicting observations whereby both too much and too little membrane order are prohibitive to optimal daptomycin binding [<a href="#rid14">14</a>]. </p><p>In enterococci, the emergence of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> nonsusceptibility is associated with diverse evolutionary pathways and mutations in the cell envelope stress response system and genes involved in phospholipid biosynthesis [<a href="#rid15">15-17</a>].</p><p>Mutations associated with <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> nonsusceptibility have been purported to be related to charge repulsion and membrane fluidity. Gain-of-function mutations in membrane biosynthesis genes, such as <em>mprF</em>, can contribute to daptomycin resistance [<a href="#rid18">18,19</a>]. This same mutation also confers a host immune evasion advantage by concurrently inhibiting cationic host defense peptides and impairing immune recognition by the innate immune system [<a href="#rid20">20,21</a>]. </p><p class="headingAnchor" id="H1294799789"><span class="h1">PHARMACOKINETICS</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> is a large molecule with a molecular mass of approximately 1.6 kDa, high protein binding (90 to 95 percent), and distribution primarily in the vascular space with a low volume of distribution of 0.1 L/kg [<a href="#rid22">22</a>]. The pharmacokinetics of daptomycin are linear up to doses of 12 mg/kg, administered intravenously for 14 days [<a href="#rid23">23</a>]. The drug is primarily excreted via the kidneys [<a href="#rid24">24</a>]. Daptomycin has an elimination half-life of approximately 8 to 9 hours in adults [<a href="#rid22">22,24</a>] compared with 6.7 hours in adolescents, 5.6 hours in children aged 7 to 11 years, and 5.3 hours in children &lt;6 years of age [<a href="#rid25">25</a>]. </p><p>The pharmacokinetics of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> in children differ compared with that in adults; children have lower total body water and blood protein concentrations [<a href="#rid26">26</a>]; this is important given daptomycin’s high protein binding and low volume of distribution. Children between 2 and 11 years demonstrate age-dependent plasma clearance of daptomycin [<a href="#rid25">25</a>]. Therefore, higher daptomycin doses are required in these patients to achieve a similar systemic exposure associated with efficacy in adults [<a href="#rid25">25</a>]. </p><p>Pharmacokinetic considerations by organ system include: </p><p class="bulletIndent1"><span class="glyph">●</span>Respiratory tract − <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> is inactivated by alveolar surfactants and therefore should not be used for bronchioalveolar pneumonia [<a href="#rid27">27</a>]. Empiric use of daptomycin in the clinical setting of pulmonary infiltrates should be avoided. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urinary tract − <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> is suitable for treatment of urinary tract infections caused by resistant gram-positive organisms; approximately 54 percent of the drug is excreted as microbiologically active drug in the urine [<a href="#rid22">22,28</a>]. (See  <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">"Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Central nervous system − <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> penetrates poorly into the cerebrospinal fluid (CSF), due to its high molecular mass and high protein binding. Meningeal inflammation does not appear to increase CSF penetration [<a href="#rid29">29</a>]. CSF concentrations have been reported to be as low as 0.45 percent [<a href="#rid30">30</a>] and 0.8 percent of plasma concentrations in patients with health care-associated meningitis [<a href="#rid31">31</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skin and soft tissue − <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> has good skin and soft tissue penetration with soft tissue concentrations of approximately 70 to 90 percent of those of the free drug in the plasma [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/3176.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bone and joint − <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> is considered to have poor bone penetration relative to its serum concentration (&lt;10 percent); however, evidence to support its use is increasing by attainment of therapeutic bone concentrations above that of the minimum inhibitory concentration of gram-positive bacteria [<a href="#rid33">33-35</a>]. In one trial including more than 140 children with osteomyelitis randomly assigned to treatment with daptomycin or comparator antibiotics (<a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, <a class="drug drug_general" data-topicid="9674" href="/z/d/drug information/9674.html" rel="external">nafcillin</a>, or equivalent), noninferiority criteria for clinical improvement at day 5 were not met; however, clinical cure rates at the end of therapy were similar between the two groups (82 versus 87 percent) [<a href="#rid36">36</a>]. (See  <a class="medical medical_review" href="/z/d/html/114350.html" rel="external">"Nonvertebral osteomyelitis in adults: Treatment"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Biofilm − <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> has variable activity against biofilms associated with <em>S. aureus</em> and vancomycin-resistant enterococci; efficacy is enhanced with combination antimicrobial therapy and novel strategies such as daptomycin microencapsulation in polymeric platforms [<a href="#rid37">37-45</a>]. Activity against biofilm associated with <em>Staphylococcus epidermidis</em> in the context of foreign material has been observed [<a href="#rid46">46-48</a>].</p><p></p><p class="headingAnchor" id="H2235969385"><span class="h1">PHARMACODYNAMICS</span></p><p class="headingAnchor" id="H2327617426"><span class="h2">General principles</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> acts via concentration-dependent bacterial killing with a prolonged postantibiotic effect (4.8 to 10.8 hours) [<a href="#rid49">49,50</a>]. The area-under-the-curve/minimum inhibitory concentration ratio (AUC/MIC) is the best pharmacokinetic/pharmacodynamic index for predicting efficacy. </p><p>For <em>S. aureus</em> infection, a murine model noted total drug AUC/MIC ratios for bacteriostasis were 388 to 537, which correlate with free drug AUC/MIC values of 31 to 43 [<a href="#rid49">49</a>]. A subsequent in vitro study of methicillin-resistant <em>S. aureus </em>found free drug AUC/MIC ratios for bacteriostasis of 37.2 ± 16.5 [<a href="#rid51">51</a>]. Despite studies failing to consistently show a clear relationship between exposure and outcome across different infection syndromes, a total drug AUC/MIC &gt;666 has been associated with lower mortality [<a href="#rid52">52</a>] and trough concentrations &lt;3.2 mg/L (at steady state) have been associated with poor clinical outcomes [<a href="#rid53">53</a>]. </p><p>For enterococcal bloodstream infection, a free drug AUC/MIC target of &gt;27.4 predicted survival at 30 days [<a href="#rid54">54</a>]. Monte Carlo simulation demonstrates that, even with <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> doses of 12 mg/kg/day, &gt;90 percent target attainment is only possible for isolates with MIC ≤2 mg/L (measured by Etest). Therefore, monotherapy would be unable to achieve adequate exposure against the entire wild-type population of enterococcal strains. Combination therapy has been proposed as an alternative way to reduce the free drug AUC/MIC targets that allow for a &gt;90 percent target attainment, using 12 mg/kg/day for strains with MIC of 4 mg/L [<a href="#rid55">55</a>].</p><p class="headingAnchor" id="H2749680380"><span class="h2">Therapeutic drug monitoring</span><span class="headingEndMark"> — </span>Data supporting use of therapeutic drug monitoring (TDM) for <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> are limited [<a href="#rid56">56</a>]. Further study of TDM is warranted to help optimize dosing, prevent toxicity, and avoid emergence of resistance, particularly given unpredictable serum daptomycin levels and increasing use of high-dose therapy [<a href="#rid52">52,53,57-60</a>]. This need is especially important for use of daptomycin in the context of altered pharmacokinetics, such as renal impairment, hemodialysis, continuous renal replacement therapy, extremes of body weight, hypoalbuminemia, and critical illness. A major limitation to the clinical implementation of daptomycin TDM is lack of accessibility to timely bioanalytic assays [<a href="#rid61">61</a>]. </p><p class="headingAnchor" id="H2568989565"><span class="h1">CLINICAL USE</span></p><p class="headingAnchor" id="H1341820440"><span class="h2">General principles</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> may be used for (1) targeted treatment against gram-positive infections for situations in which standard therapy is not possible due to bacterial resistance or intolerance to other antibiotic agents or (2) empiric treatment of serious infection in patients known to be colonized with a resistant gram-positive organism. </p><p><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> should never be used for treatment of bronchopneumonia, since pulmonary surfactant greatly reduces binding to the bacterial cell membrane and thereby preventing activity of the drug. However, daptomycin does have efficacy in hematogenous pulmonary infections, such as that arising from septic pulmonary emboli [<a href="#rid62">62</a>]. </p><p>Issues related to dosing are discussed below. (See <a class="local">'Dosing'</a> below.)</p><p>Patients on <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> should be monitored clinically for development of muscle pain or weakness, and should undergo creatine phosphokinase (CPK) monitoring during drug administration. For patients on statin therapy, issues related to consideration of temporary statin discontinuation during daptomycin therapy are discussed below. (See <a class="local">'Monitoring'</a> below and <a class="local">'Statins'</a> below.) </p><p><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> is approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for use in complicated skin and soft tissue infections and <em>S. aureus</em> bacteremia. </p><p>There has been increasing clinical experience with off-label use of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> for a wider spectrum of infection syndromes. These include left-sided and prosthetic valve endocarditis, bone and joint infections (including infection involving prosthetic material), complicated urinary tract infections, and other deep-seated infections [<a href="#rid63">63-70</a>]. With the exception of uncomplicated urinary tract infections (where daptomycin achieves relatively high urinary concentrations, allowing lower doses to be used effectively) [<a href="#rid71">71</a>], pathogen susceptibility and daptomycin exposure at the site of infection must be considered carefully when selecting an off-label dose regimen. Increasing use of higher daptomycin doses (&gt;6 mg/kg/day) has been reported for the treatment of osteomyelitis and prosthetic joint infections [<a href="#rid66">66,67,72</a>]. Furthermore, the pharmacokinetic alterations in critical illness (in patients without renal impairment) support higher dosing. </p><p>The Infectious Diseases Society of America 2011 guidelines suggest daily doses of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> up to 10 mg/kg in cases of endocarditis or complicated bacteremia caused by methicillin-resistant <em>S. aureus </em>(MRSA) [<a href="#rid73">73</a>]. In addition, daptomycin may be used in the setting of <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a> failure (clinical or microbiologic); the higher dose of 10 mg/kg has been used in this setting due to the association of concurrent emergence of nonsusceptibility to vancomycin and daptomycin. (See  <a class="medical medical_review" href="/z/d/html/3176.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of skin and soft tissue infections"</a> and  <a class="medical medical_review" href="/z/d/html/3164.html" rel="external">"Methicillin-resistant Staphylococcus aureus (MRSA) in adults: Treatment of bacteremia"</a>.)</p><p>Further expanded use of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> includes the directed treatment of vancomycin-resistant enterococci (VRE) pathogens. Complicated infections caused by VRE represent a distinct clinical challenge, with limited effective antimicrobial options available and a propensity to affect vulnerable immunocompromised patients. Although an effective dosing regimen appropriate for <em>Enterococcus</em> spp has not been identified, with concerns regarding treatment failure and emergence of resistance, there are reports of clinical success, especially associated with the use of high dose daptomycin (up to 12 mg/kg/day) [<a href="#rid74">74,75</a>]. Until future clinical studies provide more guidance in relation to the clinical efficacy of optimized dosing regimens, close clinical monitoring should accompany the use of high-dose daptomycin when treating all enterococcal infections. (See  <a class="medical medical_review" href="/z/d/html/3163.html" rel="external">"Treatment of enterococcal infections"</a>.)</p><p>There is increasing evidence to support the effectiveness and tolerability of high-dose <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> therapy (≥8 mg/kg). However, available data are limited to small, retrospective studies. In general, the frequency of CPK elevation among patients treated with high-dose daptomycin therapy has been reported at rates of 2.8 to 3.2 percent [<a href="#rid74">74,76</a>]. One retrospective cohort study including 60 patients treated with high-dose daptomycin (≥10 mg/kg/day) noted no increase in CPK elevation [<a href="#rid77">77</a>]. </p><p class="headingAnchor" id="H3095420807"><span class="h2">Dosing</span></p><p class="headingAnchor" id="H1942641368"><span class="h3">Standard dosing</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> is approved by the FDA and the EMA for use in complicated skin and soft tissue infections (adult dose: 4 mg/kg intravenously [IV] every 24 hours) and <em>S. aureus</em> bacteremia (adult dose: 6 mg/kg IV every 24 hours) associated with either complicated skin and soft tissue infections or right-sided endocarditis. The same indications are approved for children 1 to 17 years of age, with the exception of right-sided endocarditis. Pediatric dosing is summarized in the table (<a class="graphic graphic_table graphicRef130846" href="/z/d/graphic/130846.html" rel="external">table 2</a>). </p><p class="headingAnchor" id="H2809666061"><span class="h3">Renal impairment</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> dose adjustment is required in renal impairment:</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Creatinine clearance ≥30 mL/minute</strong> − For patients with creatinine clearance ≥30 mL/minute, <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> should be administered every 24 hours. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Creatinine clearance &lt;30 mL/minute</strong> – For patients with creatinine clearance &lt;30 mL/minute, <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> should be administered every 48 hours. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemodialysis </strong>– For patients on hemodialysis, <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> should be administered three times per week following dialysis. For the 72-hour interdialytic period that occurs during three-times weekly hemodialysis, a dose increase by 50 percent should be considered [<a href="#rid78">78</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Continuous ambulatory peritoneal dialysis</strong> – For patients on continuous ambulatory peritoneal dialysis, intravenous <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> should be administered every 48 hours [<a href="#rid79">79</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Continuous renal replacement therapy</strong> – A number of different dosing approaches have been suggested in the setting of continuous renal replacement therapy (CRRT), ranging from 8 mg/kg every 48 hours for continuous venovenous hemodialysis [<a href="#rid80">80</a>] to 8 mg/kg every 24 hours for continuous venovenous hemodiafiltration [<a href="#rid81">81</a>]. A subsequent study suggested that 6 mg/kg every 24 hours, with a CRRT dose of 30 to 35 mL/h/kg, provided the best balance of efficacy and toxicity when treating <em>S. aureus</em> [<a href="#rid82">82</a>]. (See  <a class="medical medical_review" href="/z/d/html/1932.html" rel="external">"Drug removal in continuous kidney replacement therapy"</a>.) </p><p></p><p class="headingAnchor" id="H4111132100"><span class="h3">Hepatic impairment</span><span class="headingEndMark"> — </span>No adjustment is required for mild to moderate hepatic dysfunction.</p><p class="headingAnchor" id="H31012652"><span class="h3">Patients with obesity</span><span class="headingEndMark"> — </span>Data are limited regarding the optimal approach to <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> dosing in patients with obesity. The FDA recommends standard weight-based dosing for all patients; however, dosing daptomycin using total body weight in patients with obesity has been associated with increased risk of adverse effects [<a href="#rid83">83</a>] (see <a class="local">'Myopathy and rhabdomyolysis'</a> below). Therefore, when using daptomycin for treatment of serious infections in patients with body mass index &gt;30 mg/m<sup>2</sup>, we favor use of adjusted body weight to maintain adequate drug concentrations and to limit adverse effects and toxicity (<a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">calculator 1</a>) [<a href="#rid84">84</a>]. </p><p>Data on clinical outcomes for use of adjusted body weight are limited; retrospective data suggest such outcomes appear to be comparable among patients dosed via adjusted body weight versus total body weight [<a href="#rid84">84</a>]. Dosing based on ideal body weight has been associated with similar clinical and microbiologic outcomes compared with actual body weight [<a href="#rid85">85</a>].</p><p class="headingAnchor" id="H1546564073"><span class="h3">Critical illness</span><span class="headingEndMark"> — </span>Pharmacokinetic changes in critically ill patients may affect achievement of adequate <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> exposure [<a href="#rid86">86,87</a>]. Factors such as augmented renal clearance, increased unbound fraction of daptomycin, and increased volume of distribution may warrant higher daptomycin doses and use of therapeutic drug monitoring [<a href="#rid87">87-89</a>]. Critically ill patients with MRSA bacteremia treated with 6 to 8 mg/kg have been found to have inadequate daptomycin exposure [<a href="#rid89">89</a>]. Therefore, we favor higher daptomycin doses (up to 10 to 12 mg/kg) in critically ill patients [<a href="#rid56">56,89-91</a>].</p><p class="headingAnchor" id="H610632022"><span class="h3">Pregnancy and breastfeeding</span><span class="headingEndMark"> — </span>Data on the use of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> during pregnancy are limited. Case reports have described successful use during the second and third trimesters of pregnancy, without fetal adverse effects [<a href="#rid92">92-94</a>]. </p><p>Low concentrations of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> have been detected in breast milk (0.1 percent of the maternal dose) [<a href="#rid95">95-97</a>]; daptomycin is felt to be unlikely to cause adverse effects in breastfed infants [<a href="#rid98">98</a>]. A small number of case reports have described no adverse effects among breastfed infants during treatment and follow-up [<a href="#rid95">95,96</a>]. </p><p class="headingAnchor" id="H3561800975"><span class="h2">Role of combination therapy</span><span class="headingEndMark"> — </span>The role of combination therapy of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> with other antimicrobials continues to show promise in both in vitro and in vivo studies, which have demonstrated enhanced bacterial killing and prevention of daptomycin resistance. Many studies have focused on the treatment of MRSA infection [<a href="#rid99">99,100</a>], however, combination therapy for VRE [<a href="#rid43">43,55,101</a>] and viridans-group streptococci have also been described [<a href="#rid102">102</a>]. (See <a class="local">'Resistance'</a> above.)</p><p>Overall, combination therapy with <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> and a beta-lactam antibiotic appear to be the most promising, although further clinical trials are needed. <a class="drug drug_general" data-topicid="8477" href="/z/d/drug information/8477.html" rel="external">Fosfomycin</a> in combination with daptomycin has also shown some promise, providing synergistic therapeutic activity against both MRSA and VRE infections [<a href="#rid43">43,103-107</a>]. Other agents with support for use in combination with daptomycin include <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">gentamicin</a>, <a class="drug drug_general" data-topicid="9785" href="/z/d/drug information/9785.html" rel="external">trimethoprim-sulfamethoxazole</a>, rifampicin, <a class="drug drug_general" data-topicid="8648" href="/z/d/drug information/8648.html" rel="external">fusidic acid</a>, and <a class="drug drug_general" data-topicid="10283" href="/z/d/drug information/10283.html" rel="external">linezolid</a> [<a href="#rid41">41,108</a>].</p><p class="headingAnchor" id="H227351092"><span class="h1">MONITORING</span><span class="headingEndMark"> — </span>Patients receiving <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> should be monitored for muscle pain or weakness, new or <em>worsening</em> peripheral neuropathy, and signs or symptoms of eosinophilic pneumonia. Routine laboratory monitoring includes baseline and weekly creatine phosphokinase (CPK), basic metabolic panel, and complete blood count. More frequent CPK monitoring (twice weekly) is warranted for patients with baseline renal impairment and/or patients on concomitant statin therapy. Daptomycin should be discontinued in patients with symptomatic myopathy and CPK ≥5 times the upper limit of normal (ULN; or ≥1000 units/L), or in asymptomatic patients with CPK ≥10 times the ULN (or ≥2000 units/L).</p><p class="headingAnchor" id="H2009405022"><span class="h1">ADVERSE EFFECTS</span><span class="headingEndMark"> — </span>The most important severe adverse effects of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> include muscle toxicity (eg, myopathy/rhabdomyolysis) and eosinophilic pneumonia. Other severe adverse effects include drug reaction with eosinophilia and systemic symptoms (DRESS), tubulointerstitial nephritis, peripheral neuropathy, and neutropenia [<a href="#rid109">109-111</a>]. </p><p>Less severe adverse effects include constipation, nausea, vomiting, and headache [<a href="#rid112">112</a>]. </p><p class="headingAnchor" id="H1429386525"><span class="h2">Myopathy and rhabdomyolysis</span><span class="headingEndMark"> — </span>Daptomycin-induced myopathy has been described in 2 to 14 percent of patients receiving <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> [<a href="#rid113">113</a>] and can occur in patients with normal or abnormal baseline kidney function [<a href="#rid114">114</a>]. Rhabdomyolysis has been reported in up to 5 percent of treated patients receiving daptomycin [<a href="#rid22">22,115-117</a>]. </p><p>Factors conferring increased risk for daptomycin-associated myopathy or rhabdomyolysis include [<a href="#rid83">83,113,118</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Baseline renal impairment − Data on the risk for <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> toxicity in patients with renal impairment are limited and conflicting. In one retrospective study including 108 patients with renal impairment treated with daptomycin, a higher incidence of creatine phosphokinase (CPK) elevation was observed among those who received high-dose daptomycin (≥9 mg/kg) than among those who received standard dose (&lt;9 mg/kg) (10.8 versus 1.6 percent); however, follow-up CPK levels were available for only 66 percent of patients [<a href="#rid119">119</a>]. In contrast, a cohort study including 50 patients with renal impairment treated with ≥7.5 mg/kg observed only one patient with CPK elevation [<a href="#rid120">120</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Concomitant statin administration − Concomitant administration of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> with HMG-CoA reductase inhibitors (“statins”) may increase the risk of CPK elevation and myopathy. Patients receiving daptomycin in the setting of concomitant statin use warrant careful CPK monitoring. Issues related to temporary statin discontinuation are discussed below. (See <a class="local">'Monitoring'</a> above and <a class="local">'Statins'</a> below and  <a class="medical medical_review" href="/z/d/html/6833.html" rel="external">"Statin muscle-related adverse events"</a>.)</p><p></p><p class="bulletIndent1">In a case-control study, patients treated with <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> who developed myopathy (CPK above the upper limit of normal [ULN]) during treatment were matched with controls who were treated with daptomycin but did not develop myopathy; statin coadministration was an independent risk factor for myopathy (odds ratio 2.60) [<a href="#rid113">113</a>]. However, a number of retrospective studies have observed no increased risk of CPK elevation with concomitant statin use [<a href="#rid121">121-126</a>], including in the setting of high-dose daptomycin therapy (≥10 mg/kg/day) [<a href="#rid77">77</a>]. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Obesity − In patients with obesity, <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> has been associated with higher rates of CPK elevation, rhabdomyolysis, and drug discontinuation when dosed based on total body weight [<a href="#rid83">83,113</a>]. In obesity, daptomycin<sub> </sub>peak concentration and area under the curve values are increased [<a href="#rid84">84,127</a>], while the volume of distribution remains unchanged [<a href="#rid84">84</a>], resulting in a potential increase in daptomycin exposure [<a href="#rid127">127,128</a>]. </p><p></p><p class="bulletIndent1">Issues related to <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> dosing in patients with obesity are discussed above. (See <a class="local">'Patients with obesity'</a> above.)</p><p></p><p>Daptomycin-induced myopathy may develop with or without symptoms. In symptomatic patients, clinical manifestations range from mild myalgias (with or without mild weakness), to chronic myopathy with severe weakness, to massive rhabdomyolysis with acute renal failure [<a href="#rid129">129-132</a>]. In addition, patients with rhabdomyolysis may have dark urine (red to brown) due to myoglobinuria. (See  <a class="medical medical_review" href="/z/d/html/5166.html" rel="external">"Drug-induced myopathies"</a> and  <a class="medical medical_review" href="/z/d/html/5169.html" rel="external">"Rhabdomyolysis: Clinical manifestations and diagnosis"</a>.)</p><p>Elevation in serum CPK concentration may occur in the presence or absence of symptoms. In one case-control study including 128 patients with daptomycin-associated myopathy, the mean duration of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> administration before CPK elevation was 16.7 days (range 1 to 58 days) [<a href="#rid113">113</a>].</p><p>The diagnosis of daptomycin-induced myopathy is based on clinical manifestations and CPK elevation (at least five times the ULN). Management consists of drug discontinuation. Symptoms generally resolve within two to three days, although CPK elevation may persist up for to two weeks. (See  <a class="medical medical_review" href="/z/d/html/5166.html" rel="external">"Drug-induced myopathies"</a>.)</p><p>The diagnosis of rhabdomyolysis is established based on CPK elevation in the setting of an acute neuromuscular illness and/or dark urine. Issues related to management of rhabdomyolysis are discussed further separately. (See  <a class="medical medical_review" href="/z/d/html/5169.html" rel="external">"Rhabdomyolysis: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/14036.html" rel="external">"Prevention and treatment of heme pigment-induced acute kidney injury (including rhabdomyolysis)"</a>.)</p><p>Patients on <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> should be monitored clinically for development of muscle pain or weakness and should undergo CPK monitoring during drug administration. For patients on statin therapy, issues related to consideration of temporary statin discontinuation during daptomycin therapy are discussed below. (See <a class="local">'Monitoring'</a> above and <a class="local">'Statins'</a> below.) </p><p><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> should be discontinued in patients with symptomatic myopathy (eg, weakness and pain) and an elevated CPK ≥5 times the ULN (or ≥1000 units/L) or in patients without symptoms with an elevated CPK ≥10 times the ULN (or ≥2000 units/L) [<a href="#rid24">24</a>].</p><p class="headingAnchor" id="H1885755161"><span class="h2">Eosinophilic pneumonia</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> is one of the most common drugs implicated in drug-induced eosinophilic pneumonia [<a href="#rid133">133</a>]. The incidence may range between 1.7 and 4.8 percent [<a href="#rid134">134,135</a>]. Reported associated patient characteristics include male sex, baseline renal dysfunction, older age, presence of hypertension, and duration of treatment &gt;2 weeks at symptom onset [<a href="#rid134">134,136,137</a>].</p><p>Overall, drug-induced eosinophilic pneumonia is rare. One retrospective review noted 228 cases were reported between 1990 and 2017, of which the authors reviewed 196; of these, 32 cases were attributed to <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> [<a href="#rid133">133</a>]. Between 2004 and 2010, the US Food and Drug Administration (FDA) identified six cases reported to its adverse events reporting system [<a href="#rid138">138</a>]. </p><p>The pathophysiology is not well understood. It has been proposed that accumulation of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> binding to pulmonary surfactant may cause cellular damage, oxidant injury, and lung epithelial inflammation. Alternatively, daptomycin may induce an allergic reaction causing the release of T lymphocytes, followed by interleukins and eosinophil migration [<a href="#rid136">136,139-141</a>]. It is unclear whether there is an association between the concentration of daptomycin (in serum, lung tissue, or epithelial lining fluid) and the likelihood of developing eosinophilic pneumonia. </p><p>Clinical data are conflicting regarding the correlation between <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> dose and risk of eosinophilic pneumonia. One 2016 systematic review identified no correlation [<a href="#rid137">137</a>]. In contrast, a 2021 retrospective study including 229 patients with osteoarticular infections identified a correlation among patients who received a total cumulative daptomycin dose &gt;10 g (hazard ratio 5.3, 95% CI 1.1-24.6) [<a href="#rid135">135</a>]. In a 2022 retrospective review including 330 patients (of whom than 40 percent had body mass index &gt;30 kg/m<sup>2</sup>), eosinophilic pneumonia occurred in 11.5 percent of patients after a primary course of daptomycin at a median of 26 days (range 2 to 60 days) and 16 percent of patients who received a second course of daptomycin at a median of 3 days (range 2 to 58 days) after re-exposure [<a href="#rid142">142</a>].</p><p>Clinical manifestations may include fever (57 to 100 percent), hypoxia (40 to 87 percent), and dyspnea (75 to 94 percent) [<a href="#rid134">134,136,137</a>]. Physical examination may demonstrate fine crackles on chest auscultation. Symptoms typically develop two to four weeks after initiation of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a>; however, some patients present subacutely with average time of five months between symptom onset to diagnosis [<a href="#rid133">133,136,137</a>]. (See  <a class="medical medical_review" href="/z/d/html/4374.html" rel="external">"Idiopathic acute eosinophilic pneumonia"</a> and  <a class="medical medical_review" href="/z/d/html/4360.html" rel="external">"Chronic eosinophilic pneumonia"</a>.)</p><p>Chest radiography may be notable for pulmonary infiltrates or organizing pneumonia [<a href="#rid143">143</a>]. In one series including 49 cases, chest radiography demonstrated findings consistent with chronic eosinophilic pneumonia, including multiple subpleural reticulonodular infiltrates and diffuse bilateral pulmonary infiltrates with ground-glass opacities; however, pleural effusion, a feature of acute eosinophilic pneumonia, was also observed in two-thirds of cases [<a href="#rid136">136</a>]. </p><p>Diagnostic evaluation may include bronchoscopy with bronchoalveolar lavage (BAL) for evaluation of eosinophils. However, in one series, BAL demonstrated &gt;25 percent eosinophils (a criterion for the diagnosis of drug-induced eosinophilic pneumonia) in less than half of cases [<a href="#rid136">136</a>]. The role of peripheral blood eosinophilia to predict daptomycin-related eosinophilic pneumonia is uncertain. In a retrospective review including 330 patients, 81.5 percent developed peripheral eosinophilia during <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> treatment; the authors suggested that eosinophilia ≥5 percent may be a risk factor for the development of eosinophilic pneumonia and as a predictor that eosinophilic pneumonia may occur on re-exposure to daptomycin [<a href="#rid142">142</a>].</p><p>Management consists of supportive care (including mechanical ventilation in some cases), drug discontinuation, and systemic glucocorticoid therapy; in three series including 101 cases, all patients recovered [<a href="#rid134">134,136,137</a>].</p><p class="headingAnchor" id="H2539845896"><span class="h1">DRUG INTERACTIONS</span></p><p class="headingAnchor" id="H3981628104"><span class="h2">General principles</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> is neither an inducer nor an inhibitor of the hepatic CYP450 system. </p><p><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> may falsely prolong prothrombin time and elevate international normalized ratio, depending on daptomycin serum concentrations and the recombinant thromboplastin reagents used [<a href="#rid144">144</a>]. </p><p>Additional information on drug interactions may be found using the drug interactions tool within UpToDate.</p><p class="headingAnchor" id="H4136046362"><span class="h2">Statins</span><span class="headingEndMark"> — </span>Administration of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> with concomitant statin therapy has been variably reported to increase the risk of creatine phosphokinase and myopathy [<a href="#rid145">145</a>]. (See <a class="local">'Myopathy and rhabdomyolysis'</a> above.)</p><p>In general, we do not favor temporary statin discontinuation for patients treated with <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> doses ≤8 mg/kg/day. For patients receiving higher daptomycin doses (&gt;8 mg/kg/day), particularly if the planned treatment duration is ≥14 days, we consider temporary statin discontinuation; the decision should be individualized based on clinical factors including cardiovascular risk.</p><p class="headingAnchor" id="H324711363"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> is a lipopeptide antimicrobial with activity against gram-positive organisms, including antimicrobial-resistant pathogens such as methicillin-resistant <em>Staphylococcus aureus</em> and vancomycin-resistant <em>Enterococcus</em> spp. The primary mechanism of action is calcium-dependent depolarization of the bacterial cell membrane. The drug has a lipophilic tail that binds and inserts itself into the bacterial membrane, forming a channel causing efflux of intracellular potassium and subsequent cell membrane depolarization. (See <a class="local">'Introduction'</a> above and <a class="local">'Mechanism of action'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> may be used for (1) targeted treatment against gram-positive infections for situations in which standard therapy is not possible due to bacterial resistance or intolerance to other antibiotic agents or (2) empiric treatment of serious infection in patients known to be colonized with a resistant gram-positive organism. Daptomycin should never be used for treatment of bronchopneumonia, since pulmonary surfactant greatly reduces binding to the bacterial cell membrane and thereby preventing activity of the drug. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">Daptomycin</a> is administered parenterally. The half-life is approximately eight hours in adults and the drug is primarily excreted unchanged via the kidneys. Dose adjustment is required for renal impairment but not for mild to moderate hepatic dysfunction. (See <a class="local">'Pharmacokinetics'</a> above and <a class="local">'Pharmacodynamics'</a> above and <a class="local">'Dosing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Patients receiving <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> should be monitored for muscle pain or weakness, new or worsening peripheral neuropathy, and signs or symptoms of eosinophilic pneumonia. Routine laboratory monitoring includes baseline and weekly creatine phosphokinase (CPK), basic metabolic panel, and complete blood count. More frequent CPK monitoring (twice weekly) is warranted for patients with baseline renal impairment and/or patients on concomitant statin therapy. Daptomycin should be discontinued in patients with symptomatic myopathy and CPK ≥5 times the upper limit of normal (ULN; or ≥1000 units/L), or in asymptomatic patients with CPK ≥10 times the ULN (or ≥2000 units/L). (See <a class="local">'Monitoring'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Important adverse effects of <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> include muscle toxicity (eg, myopathy/rhabdomyolysis) and eosinophilic pneumonia. Factors conferring increased risk for myopathy/rhabdomyolysis include baseline renal impairment, concomitant statin administration, and obesity. (See <a class="local">'Adverse effects'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In general, we do not favor temporary statin discontinuation for patients treated with <a class="drug drug_general" data-topicid="9304" href="/z/d/drug information/9304.html" rel="external">daptomycin</a> doses ≤8 mg/kg/day. For patients receiving higher daptomycin doses (&gt;8 mg/kg/day), particularly if the planned treatment duration is ≥14 days, we consider temporary statin discontinuation; the decision should be individualized based on clinical factors including cardiovascular risk. (See <a class="local">'Statins'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Wootton M, MacGowan AP, Walsh TR. Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates. Antimicrob Agents Chemother 2006; 50:4195.</a></li><li><a class="nounderline abstract_t">Dandekar PK, Tessier PR, Williams P, et al. Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model. J Antimicrob Chemother 2003; 52:405.</a></li><li><a class="nounderline abstract_t">Humphries RM, Pollett S, Sakoulas G. A current perspective on daptomycin for the clinical microbiologist. Clin Microbiol Rev 2013; 26:759.</a></li><li><a class="nounderline abstract_t">Mascio CT, Alder JD, Silverman JA. Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells. Antimicrob Agents Chemother 2007; 51:4255.</a></li><li><a class="nounderline abstract_t">Sader HS, Jones RN. Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus. Diagn Microbiol Infect Dis 2012; 73:212.</a></li><li><a class="nounderline abstract_t">Jiang JH, Dexter C, Cameron DR, et al. Evolution of Daptomycin Resistance in Coagulase-Negative Staphylococci Involves Mutations of the Essential Two-Component Regulator WalKR. Antimicrob Agents Chemother 2019; 63.</a></li><li class="breakAll">The European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 10.0, 2020. http://www.eucast.org (Accessed on November 10, 2020).</li><li class="breakAll">Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Thirtieth Informational Supplement M100-S30. CLSI, Wayne, PA, USA. 2020. http://em100.edaptivedocs.net/dashboard.aspx (Accessed on November 10, 2020).</li><li><a class="nounderline abstract_t">Turnidge J, Kahlmeter G, Cantón R, et al. Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper. Clin Microbiol Infect 2020; 26:1039.</a></li><li><a class="nounderline abstract_t">Humphries RM. The New, New Daptomycin Breakpoint for Enterococcus spp. J Clin Microbiol 2019; 57.</a></li><li><a class="nounderline abstract_t">Hines KM, Shen T, Ashford NK, et al. Occurrence of cross-resistance and β-lactam seesaw effect in glycopeptide-, lipopeptide- and lipoglycopeptide-resistant MRSA correlates with membrane phosphatidylglycerol levels. J Antimicrob Chemother 2020; 75:1182.</a></li><li><a class="nounderline abstract_t">Kelley PG, Gao W, Ward PB, Howden BP. Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother 2011; 66:1057.</a></li><li><a class="nounderline abstract_t">Stefani S, Campanile F, Santagati M, et al. Insights and clinical perspectives of daptomycin resistance in Staphylococcus aureus: A review of the available evidence. Int J Antimicrob Agents 2015; 46:278.</a></li><li><a class="nounderline abstract_t">Bayer AS, Schneider T, Sahl HG. Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall. Ann N Y Acad Sci 2013; 1277:139.</a></li><li><a class="nounderline abstract_t">Arias CA, Panesso D, McGrath DM, et al. Genetic basis for in vivo daptomycin resistance in enterococci. N Engl J Med 2011; 365:892.</a></li><li><a class="nounderline abstract_t">Prater AG, Mehta HH, Kosgei AJ, et al. Environment Shapes the Accessible Daptomycin Resistance Mechanisms in Enterococcus faecium. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Hollenbeck BL, Rice LB. Intrinsic and acquired resistance mechanisms in enterococcus. Virulence 2012; 3:421.</a></li><li><a class="nounderline abstract_t">Ernst CM, Peschel A. MprF-mediated daptomycin resistance. Int J Med Microbiol 2019; 309:359.</a></li><li><a class="nounderline abstract_t">Thitiananpakorn K, Aiba Y, Tan XE, et al. Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA). Sci Rep 2020; 10:16107.</a></li><li><a class="nounderline abstract_t">Patton T, Jiang JH, Lundie RJ, et al. Daptomycin-resistant Staphylococcus aureus clinical isolates are poorly sensed by dendritic cells. Immunol Cell Biol 2020; 98:42.</a></li><li><a class="nounderline abstract_t">Jiang JH, Bhuiyan MS, Shen HH, et al. Antibiotic resistance and host immune evasion in Staphylococcus aureus mediated by a metabolic adaptation. Proc Natl Acad Sci U S A 2019; 116:3722.</a></li><li><a class="nounderline abstract_t">Dvorchik BH, Brazier D, DeBruin MF, Arbeit RD. Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects. Antimicrob Agents Chemother 2003; 47:1318.</a></li><li><a class="nounderline abstract_t">Benvenuto M, Benziger DP, Yankelev S, Vigliani G. Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers. Antimicrob Agents Chemother 2006; 50:3245.</a></li><li class="breakAll">Daptomycin (Cubicin) Product Information. Merck and Co, Inc; Whitehouse, NJ 8/2020.</li><li><a class="nounderline abstract_t">Abdel-Rahman SM, Benziger DP, Jacobs RF, et al. Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections. Pediatr Infect Dis J 2008; 27:330.</a></li><li><a class="nounderline abstract_t">Principi N, Caironi M, Venturini F, et al. Daptomycin in paediatrics: current knowledge and the need for future research. J Antimicrob Chemother 2015; 70:643.</a></li><li><a class="nounderline abstract_t">Silverman JA, Mortin LI, Vanpraagh AD, et al. Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 2005; 191:2149.</a></li><li><a class="nounderline abstract_t">Eisenstein BI. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Expert Opin Investig Drugs 2004; 13:1159.</a></li><li><a class="nounderline abstract_t">Cottagnoud P, Pfister M, Acosta F, et al. Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis. Antimicrob Agents Chemother 2004; 48:3928.</a></li><li><a class="nounderline abstract_t">Piva S, Di Paolo A, Galeotti L, et al. Daptomycin Plasma and CSF Levels in Patients with Healthcare-Associated Meningitis. Neurocrit Care 2019; 31:116.</a></li><li><a class="nounderline abstract_t">Kullar R, Chin JN, Edwards DJ, et al. Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections. Antimicrob Agents Chemother 2011; 55:3505.</a></li><li><a class="nounderline abstract_t">Kim A, Suecof LA, Sutherland CA, et al. In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers. Antimicrob Agents Chemother 2008; 52:3941.</a></li><li><a class="nounderline abstract_t">Montange D, Berthier F, Leclerc G, et al. Penetration of daptomycin into bone and synovial fluid in joint replacement. Antimicrob Agents Chemother 2014; 58:3991.</a></li><li><a class="nounderline abstract_t">Grillon A, Argemi X, Gaudias J, et al. Bone penetration of daptomycin in diabetic patients with bacterial foot infections. Int J Infect Dis 2019; 85:127.</a></li><li><a class="nounderline abstract_t">Traunmüller F, Schintler MV, Metzler J, et al. Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections. J Antimicrob Chemother 2010; 65:1252.</a></li><li><a class="nounderline abstract_t">Bradley JS, Arrieta AC, Digtyar VA, et al. Daptomycin for Pediatric Gram-Positive Acute Hematogenous Osteomyelitis. Pediatr Infect Dis J 2020; 39:814.</a></li><li><a class="nounderline abstract_t">Zheng JX, Tu HP, Sun X, et al. In vitro activities of telithromycin against Staphylococcus aureus biofilms compared with azithromycin, clindamycin, vancomycin and daptomycin. J Med Microbiol 2020; 69:120.</a></li><li><a class="nounderline abstract_t">John AK, Baldoni D, Haschke M, et al. Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin. Antimicrob Agents Chemother 2009; 53:2719.</a></li><li><a class="nounderline abstract_t">Woischnig AK, Gonçalves LM, Ferreira M, et al. Acrylic microparticles increase daptomycin intracellular and in vivo anti-biofilm activity against Staphylococcus aureus. Int J Pharm 2018; 550:372.</a></li><li><a class="nounderline abstract_t">Parra-Ruiz J, Bravo-Molina A, Peña-Monje A, Hernández-Quero J. Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm. J Antimicrob Chemother 2012; 67:2682.</a></li><li><a class="nounderline abstract_t">Siala W, Rodriguez-Villalobos H, Fernandes P, et al. Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in In Vitro Static and Dynamic Models. Antimicrob Agents Chemother 2018; 62.</a></li><li><a class="nounderline abstract_t">Ravn C, Ferreira IS, Maiolo E, et al. Microcalorimetric detection of staphylococcal biofilm growth on various prosthetic biomaterials after exposure to daptomycin. J Orthop Res 2018; 36:2809.</a></li><li><a class="nounderline abstract_t">Jahanbakhsh S, Singh NB, Yim J, et al. Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an In Vitro Biofilm Model. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Dall GF, Tsang SJ, Gwynne PJ, et al. Unexpected synergistic and antagonistic antibiotic activity against Staphylococcus biofilms. J Antimicrob Chemother 2018; 73:1830.</a></li><li><a class="nounderline abstract_t">Boudjemaa R, Briandet R, Revest M, et al. New Insight into Daptomycin Bioavailability and Localization in Staphylococcus aureus Biofilms by Dynamic Fluorescence Imaging. Antimicrob Agents Chemother 2016; 60:4983.</a></li><li><a class="nounderline abstract_t">Stewart PS, Davison WM, Steenbergen JN. Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm. Antimicrob Agents Chemother 2009; 53:3505.</a></li><li><a class="nounderline abstract_t">Domínguez-Herrera J, Docobo-Pérez F, López-Rojas R, et al. Efficacy of daptomycin versus vancomycin in an experimental model of foreign-body and systemic infection caused by biofilm producers and methicillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother 2012; 56:613.</a></li><li><a class="nounderline abstract_t">Ozturk B, Gunay N, Ertugrul BM, Sakarya S. Effects of vancomycin, daptomycin, and tigecycline on coagulase-negative staphylococcus biofilm and bacterial viability within biofilm: an in vitro biofilm model. Can J Microbiol 2016; 62:735.</a></li><li><a class="nounderline abstract_t">Safdar N, Andes D, Craig WA. In vivo pharmacodynamic activity of daptomycin. Antimicrob Agents Chemother 2004; 48:63.</a></li><li><a class="nounderline abstract_t">Pankuch GA, Jacobs MR, Appelbaum PC. Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates. Antimicrob Agents Chemother 2003; 47:3012.</a></li><li><a class="nounderline abstract_t">Bowker KE, Noel AR, MacGowan AP. Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection. J Antimicrob Chemother 2009; 64:1044.</a></li><li><a class="nounderline abstract_t">Falcone M, Russo A, Cassetta MI, et al. Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary? J Infect Chemother 2013; 19:732.</a></li><li><a class="nounderline abstract_t">Galar A, Muñoz P, Valerio M, et al. Current use of daptomycin and systematic therapeutic drug monitoring: Clinical experience in a tertiary care institution. Int J Antimicrob Agents 2019; 53:40.</a></li><li><a class="nounderline abstract_t">Avery LM, Kuti JL, Weisser M, et al. Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint. Clin Infect Dis 2019; 68:1650.</a></li><li><a class="nounderline abstract_t">Avery LM, Kuti JL, Weisser M, et al. Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia. Int J Antimicrob Agents 2019; 54:346.</a></li><li><a class="nounderline abstract_t">Abdul-Aziz MH, Alffenaar JC, Bassetti M, et al. Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper. Intensive Care Med 2020; 46:1127.</a></li><li><a class="nounderline abstract_t">Reiber C, Senn O, Müller D, et al. Therapeutic Drug Monitoring of Daptomycin: A Retrospective Monocentric Analysis. Ther Drug Monit 2015; 37:634.</a></li><li><a class="nounderline abstract_t">Yamada T, Ooi Y, Oda K, et al. Observational study to determine the optimal dose of daptomycin based on pharmacokinetic/pharmacodynamic analysis. J Infect Chemother 2020; 26:379.</a></li><li><a class="nounderline abstract_t">Barreau S, Benaboud S, Kernéis S, et al. Staphylococcus aureus osteo-articular infection: usefulness of the determination of daptomycin serum concentration to explain a treatment failure. Int J Clin Pharmacol Ther 2016; 54:923.</a></li><li><a class="nounderline abstract_t">Cojutti PG, Candoni A, Ramos-Martin V, et al. Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies. J Antimicrob Chemother 2017; 72:2342.</a></li><li><a class="nounderline abstract_t">Miyadera Y, Naito T, Yamada T, Kawakami J. Simple LC-MS/MS Methods Using Core-Shell Octadecylsilyl Microparticulate for the Quantitation of Total and Free Daptomycin in Human Plasma. Ther Drug Monit 2018; 40:589.</a></li><li><a class="nounderline abstract_t">Crass RL, Powell KL, Huang AM. Daptomycin for the treatment of Staphylococcus aureus infections complicated by septic pulmonary emboli. Diagn Microbiol Infect Dis 2019; 93:131.</a></li><li><a class="nounderline abstract_t">Gonzalez-Ruiz A, Gargalianos-Kakolyris P, Timerman A, et al. Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry. Adv Ther 2015; 32:496.</a></li><li><a class="nounderline abstract_t">Guleri A, Utili R, Dohmen P, et al. Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin(®) Outcomes Registry and Experience (EU-CORE). Infect Dis Ther 2015; 4:283.</a></li><li><a class="nounderline abstract_t">Seaton RA, Gonzalez-Ruiz A, Cleveland KO, et al. Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE. Ann Clin Microbiol Antimicrob 2016; 15:18.</a></li><li><a class="nounderline abstract_t">Malizos K, Sarma J, Seaton RA, et al. Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry. Eur J Clin Microbiol Infect Dis 2016; 35:111.</a></li><li><a class="nounderline abstract_t">Peiffer-Smadja N, Abbara S, Rizk N, et al. High-dose daptomycin in patients with infective endocarditis or sternal wound infections. Clin Microbiol Infect 2018; 24:1106.</a></li><li><a class="nounderline abstract_t">Roux S, Valour F, Karsenty J, et al. Daptomycin &gt; 6 mg/kg/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference center. BMC Infect Dis 2016; 16:83.</a></li><li><a class="nounderline abstract_t">Chang YJ, Lee MS, Lee CH, et al. Daptomycin treatment in patients with resistant staphylococcal periprosthetic joint infection. BMC Infect Dis 2017; 17:736.</a></li><li><a class="nounderline abstract_t">Byren I, Rege S, Campanaro E, et al. Randomized controlled trial of the safety and efficacy of Daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty. Antimicrob Agents Chemother 2012; 56:5626.</a></li><li><a class="nounderline abstract_t">Fisher L, North D. Effectiveness of low-dose daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections. Int J Antimicrob Agents 2009; 33:493.</a></li><li><a class="nounderline abstract_t">Hermsen ED, Mendez-Vigo L, Berbari EF, et al. A retrospective study of outcomes of device-associated osteomyelitis treated with daptomycin. BMC Infect Dis 2016; 16:310.</a></li><li><a class="nounderline abstract_t">Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis 2011; 52:e18.</a></li><li><a class="nounderline abstract_t">Casapao AM, Kullar R, Davis SL, et al. Multicenter study of high-dose daptomycin for treatment of enterococcal infections. Antimicrob Agents Chemother 2013; 57:4190.</a></li><li><a class="nounderline abstract_t">Lübbert C, Rodloff AC, Hamed K. Real-World Treatment of Enterococcal Infections with Daptomycin: Insights from a Large European Registry (EU-CORE). Infect Dis Ther 2015; 4:259.</a></li><li><a class="nounderline abstract_t">Seaton RA, Menichetti F, Dalekos G, et al. Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience. Adv Ther 2015; 32:1192.</a></li><li><a class="nounderline abstract_t">Britt NS, Potter EM, Patel N, Steed ME. Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients. Clin Infect Dis 2017; 64:605.</a></li><li><a class="nounderline abstract_t">Haselden M, Leach M, Bohm N. Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis. Ann Pharmacother 2013; 47:1342.</a></li><li><a class="nounderline abstract_t">Cardone KE, Lodise TP, Patel N, et al. Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis. Clin J Am Soc Nephrol 2011; 6:1081.</a></li><li><a class="nounderline abstract_t">Vilay AM, Grio M, Depestel DD, et al. Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis. Crit Care Med 2011; 39:19.</a></li><li><a class="nounderline abstract_t">Falcone M, Russo A, Cassetta MI, et al. Daptomycin serum levels in critical patients undergoing continuous renal replacement. J Chemother 2012; 24:253.</a></li><li><a class="nounderline abstract_t">Xie F, Li S, Cheng Z. Population pharmacokinetics and dosing considerations of daptomycin in critically ill patients undergoing continuous renal replacement therapy. J Antimicrob Chemother 2020; 75:1559.</a></li><li><a class="nounderline abstract_t">Bookstaver PB, Bland CM, Qureshi ZP, et al. Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States. Pharmacotherapy 2013; 33:1322.</a></li><li><a class="nounderline abstract_t">Fox AN, Smith WJ, Kupiec KE, et al. Daptomycin dosing in obese patients: analysis of the use of adjusted body weight versus actual body weight. Ther Adv Infect Dis 2019; 6:2049936118820230.</a></li><li><a class="nounderline abstract_t">Ng JK, Schulz LT, Rose WE, et al. Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes. Antimicrob Agents Chemother 2014; 58:88.</a></li><li><a class="nounderline abstract_t">Roberts JA, Lipman J. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 2009; 37:840.</a></li><li><a class="nounderline abstract_t">D'Avolio A, Pensi D, Baietto L, et al. Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients. Drugs 2016; 76:1161.</a></li><li><a class="nounderline abstract_t">Di Paolo A, Tascini C, Polillo M, et al. Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections. Int J Antimicrob Agents 2013; 42:250.</a></li><li><a class="nounderline abstract_t">Falcone M, Russo A, Venditti M, et al. Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis 2013; 57:1568.</a></li><li><a class="nounderline abstract_t">Soraluce A, Asín-Prieto E, Rodríguez-Gascón A, et al. Population pharmacokinetics of daptomycin in critically ill patients. Int J Antimicrob Agents 2018; 52:158.</a></li><li><a class="nounderline abstract_t">Grégoire N, Marchand S, Ferrandière M, et al. Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment. J Antimicrob Chemother 2019; 74:117.</a></li><li><a class="nounderline abstract_t">Klibanov OM, Vickery S, Nortey C. Successful treatment of infective panniculitis with daptomycin in a pregnant, morbidly obese patient. Ann Pharmacother 2014; 48:652.</a></li><li><a class="nounderline abstract_t">Shea K, Hilburger E, Baroco A, Oldfield E. Successful treatment of vancomycin-resistant Enterococcus faecium pyelonephritis with daptomycin during pregnancy. Ann Pharmacother 2008; 42:722.</a></li><li><a class="nounderline abstract_t">Stroup JS, Wagner J, Badzinski T. Use of daptomycin in a pregnant patient with Staphylococcus aureus endocarditis. Ann Pharmacother 2010; 44:746.</a></li><li><a class="nounderline abstract_t">Buitrago MI, Crompton JA, Bertolami S, et al. Extremely low excretion of daptomycin into breast milk of a nursing mother with methicillin-resistant Staphylococcus aureus pelvic inflammatory disease. Pharmacotherapy 2009; 29:347.</a></li><li><a class="nounderline abstract_t">Cesari E, Roda G, Visconti GL, et al. Daptomycin excretion into human milk. Br J Clin Pharmacol 2018; 84:394.</a></li><li><a class="nounderline abstract_t">Dei Cas M, Casagni E, Gambaro V, et al. Determination of daptomycin in human plasma and breast milk by UPLC/MS-MS. J Chromatogr B Analyt Technol Biomed Life Sci 2019; 1116:38.</a></li><li class="breakAll">Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-. Daptomycin. [Updated 2019 May 1]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK501604/ (Accessed 19 Nov 2020).</li><li><a class="nounderline abstract_t">Wang C, Ye C, Liao L, et al. Adjuvant β-Lactam Therapy Combined with Vancomycin or Daptomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: a Systematic Review and Meta-analysis. Antimicrob Agents Chemother 2020; 64.</a></li><li><a class="nounderline abstract_t">Morrisette T, Alosaimy S, Abdul-Mutakabbir JC, et al. The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA-Salvaging the Gold Standards with Combination Therapy. Antibiotics (Basel) 2020; 9.</a></li><li><a class="nounderline abstract_t">Kebriaei R, Stamper KC, Singh KV, et al. Mechanistic Insights Into the Differential Efficacy of Daptomycin Plus β-Lactam Combinations Against Daptomycin-Resistant Enterococcus faecium. J Infect Dis 2020; 222:1531.</a></li><li><a class="nounderline abstract_t">Kebriaei R, Rice SA, Stamper KC, et al. Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis/oralis in an Ex Vivo Simulated Endocarditis Vegetation Model. Antimicrob Agents Chemother 2019; 63.</a></li><li><a class="nounderline abstract_t">Yu W, Zhang J, Tong J, et al. In Vitro Antimicrobial Activity of Fosfomycin, Vancomycin and Daptomycin Alone, and in Combination, Against Linezolid-Resistant Enterococcus faecalis. Infect Dis Ther 2020; 9:927.</a></li><li><a class="nounderline abstract_t">Pujol M, Miró JM, Shaw E, et al. Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial. Clin Infect Dis 2021; 72:1517.</a></li><li><a class="nounderline abstract_t">Lee YC, Chen PY, Wang JT, Chang SC. A study on combination of daptomycin with selected antimicrobial agents: in vitro synergistic effect of MIC value of 1 mg/L against MRSA strains. BMC Pharmacol Toxicol 2019; 20:25.</a></li><li><a class="nounderline abstract_t">García-de-la-Mària C, Gasch O, Castañeda X, et al. Cloxacillin or fosfomycin plus daptomycin combinations are more active than cloxacillin monotherapy or combined with gentamicin against MSSA in a rabbit model of experimental endocarditis. J Antimicrob Chemother 2020; 75:3586.</a></li><li><a class="nounderline abstract_t">Hall Snyder AD, Werth BJ, Nonejuie P, et al. Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model. Antimicrob Agents Chemother 2016; 60:5716.</a></li><li><a class="nounderline abstract_t">Gould IM, Miró JM, Rybak MJ. Daptomycin: the role of high-dose and combination therapy for Gram-positive infections. Int J Antimicrob Agents 2013; 42:202.</a></li><li><a class="nounderline abstract_t">Skiest DJ. Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin. J Clin Microbiol 2006; 44:655.</a></li><li class="breakAll">http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm220273.htm (Accessed September 10, 2010).</li><li><a class="nounderline abstract_t">Knoll BM, Spieler PJ, Kubiak DW, Marty FM. Neutropenia associated with prolonged daptomycin use. Clin Infect Dis 2013; 56:1353.</a></li><li><a class="nounderline abstract_t">Arbeit RD, Maki D, Tally FP, et al. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis 2004; 38:1673.</a></li><li><a class="nounderline abstract_t">Dare RK, Tewell C, Harris B, et al. Effect of Statin Coadministration on the Risk of Daptomycin-Associated Myopathy. Clin Infect Dis 2018; 67:1356.</a></li><li><a class="nounderline abstract_t">Kazory A, Dibadj K, Weiner ID. Rhabdomyolysis and acute renal failure in a patient treated with daptomycin. J Antimicrob Chemother 2006; 57:578.</a></li><li><a class="nounderline abstract_t">Papadopoulos S, Ball AM, Liewer SE, et al. Rhabdomyolysis during therapy with daptomycin. Clin Infect Dis 2006; 42:e108.</a></li><li><a class="nounderline abstract_t">Katz DE, Lindfield KC, Steenbergen JN, et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract 2008; 62:1455.</a></li><li><a class="nounderline abstract_t">Pertel PE, Eisenstein BI, Link AS, et al. The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract 2009; 63:368.</a></li><li><a class="nounderline abstract_t">Rege S, Mohr J, Lamp KC, et al. Safety of daptomycin in patients completing more than 14 days of therapy: results from the Cubicin® Outcomes Registry and experience. Int J Antimicrob Agents 2013; 41:421.</a></li><li><a class="nounderline abstract_t">Tai CH, Shao CH, Chen CY, et al. Safety of high-dose daptomycin in patients with severe renal impairment. Ther Clin Risk Manag 2018; 14:493.</a></li><li><a class="nounderline abstract_t">Vlashyn OO, Lorenz AM, Sobhanie MM, et al. Safety outcomes with high-dose daptomycin in patients with acute kidney injury and/or end-stage renal disease. J Clin Pharm Ther 2021; 46:363.</a></li><li><a class="nounderline abstract_t">Kido K, Oyen AA, Beckmann MA, Brouse SD. Musculoskeletal toxicities in patients receiving concomitant statin and daptomycin therapy. Am J Health Syst Pharm 2019; 76:206.</a></li><li><a class="nounderline abstract_t">McConnell HL, Perris ET, Lowry C, et al. Effect of Concomitant 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Therapy on Creatine Phosphokinase Levels and Mortality Among Patients Receiving Daptomycin: Retrospective Cohort Study. Infect Dis Ther 2014; 3:225.</a></li><li><a class="nounderline abstract_t">Berg ML, Estes LL, Dierkhising RA, et al. Evaluation of impact of statin use on development of CPK elevation during daptomycin therapy. Ann Pharmacother 2014; 48:320.</a></li><li><a class="nounderline abstract_t">Parra-Ruiz J, Dueñas-Gutiérrez C, Tomás-Jiménez C, et al. Safety analysis of high dose (&gt;6 mg/kg/day) daptomycin in patients with concomitant statin therapy. Eur J Clin Microbiol Infect Dis 2012; 31:1771.</a></li><li><a class="nounderline abstract_t">Lehman B, Neuner EA, Heh V, Isada C. A Retrospective Multisite Case-Control Series of Concomitant Use of Daptomycin and Statins and the Effect on Creatine Phosphokinase. Open Forum Infect Dis 2019; 6:ofz444.</a></li><li><a class="nounderline abstract_t">Bland CM, Bookstaver PB, Lu ZK, et al. Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors. Antimicrob Agents Chemother 2014; 58:5726.</a></li><li><a class="nounderline abstract_t">Pai MP, Norenberg JP, Anderson T, et al. Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin. Antimicrob Agents Chemother 2007; 51:2741.</a></li><li><a class="nounderline abstract_t">Dvorchik BH, Damphousse D. The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects. J Clin Pharmacol 2005; 45:48.</a></li><li><a class="nounderline abstract_t">Oleson FB Jr, Berman CL, Kirkpatrick JB, et al. Once-daily dosing in dogs optimizes daptomycin safety. Antimicrob Agents Chemother 2000; 44:2948.</a></li><li><a class="nounderline abstract_t">Oleson FB, Berman CL, Li AP. An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes. Chem Biol Interact 2004; 150:137.</a></li><li><a class="nounderline abstract_t">Veligandla SR, Louie KR, Malesker MA, Smith PW. Muscle pain associated with daptomycin. Ann Pharmacother 2004; 38:1860.</a></li><li><a class="nounderline abstract_t">Echevarria K, Datta P, Cadena J, Lewis JS 2nd. Severe myopathy and possible hepatotoxicity related to daptomycin. J Antimicrob Chemother 2005; 55:599.</a></li><li><a class="nounderline abstract_t">Bartal C, Sagy I, Barski L. Drug-induced eosinophilic pneumonia: A review of 196 case reports. Medicine (Baltimore) 2018; 97:e9688.</a></li><li><a class="nounderline abstract_t">Pham TT, Garreau R, Craighero F, et al. Seventeen Cases of Daptomycin-Induced Eosinophilic Pneumonia in a Cohort of Patients Treated for Bone and Joint Infections: Proposal for a New Algorithm. Open Forum Infect Dis 2022; 9:ofac577.</a></li><li><a class="nounderline abstract_t">Soldevila-Boixader L, Villanueva B, Ulldemolins M, et al. Risk Factors of Daptomycin-Induced Eosinophilic Pneumonia in a Population with Osteoarticular Infection. Antibiotics (Basel) 2021; 10.</a></li><li><a class="nounderline abstract_t">Hirai J, Hagihara M, Haranaga S, et al. Eosinophilic pneumonia caused by daptomycin: Six cases from two institutions and a review of the literature. J Infect Chemother 2017; 23:245.</a></li><li><a class="nounderline abstract_t">Uppal P, LaPlante KL, Gaitanis MM, et al. Daptomycin-induced eosinophilic pneumonia - a systematic review. Antimicrob Resist Infect Control 2016; 5:55.</a></li><li class="breakAll">https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-drug-safety-communication-eosinophilic-pneumonia-associated-use-cubicin-daptomycin (Accessed on August 10, 2020).</li><li class="breakAll">US Food and Drug Administration. FDA Drug Safety Communication: Eosinophilic pneumonia associated with the use of Cubicin (daptomycin). http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm220273.htm (Accessed on November 16, 2020).</li><li><a class="nounderline abstract_t">Hayes D Jr, Anstead MI, Kuhn RJ. Eosinophilic pneumonia induced by daptomycin. J Infect 2007; 54:e211.</a></li><li><a class="nounderline abstract_t">Kakish E, Wiesner AM, Winstead PS, Benasadoun ES. Acute respiratory failure due to daptomycin induced eosinophilic pneumonia. Respir Med 2008; 1:235.</a></li><li><a class="nounderline abstract_t">West KA, Sheeti A, Tamura MacKay K, Forrest GN. Eosinophilic Syndromes Associated With Daptomycin Use: Re-exposure Hypersensitivity Pneumonitis and Prior Peripheral Eosinophilia. Open Forum Infect Dis 2022; 9:ofac065.</a></li><li><a class="nounderline abstract_t">Lal Y, Assimacopoulos AP. Two cases of daptomycin-induced eosinophilic pneumonia and chronic pneumonitis. Clin Infect Dis 2010; 50:737.</a></li><li><a class="nounderline abstract_t">Webster PS, Oleson FB Jr, Paterson DL, et al. Interaction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time/International Normalized Ratio results. Blood Coagul Fibrinolysis 2008; 19:32.</a></li><li><a class="nounderline abstract_t">Chuma M, Nakamoto A, Bando T, et al. Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis. Clin Infect Dis 2022; 75:1416.</a></li></ol></div><div id="topicVersionRevision">Topic 129183 Version 9.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17043121" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Comparative bactericidal activities of daptomycin and vancomycin against glycopeptide-intermediate Staphylococcus aureus (GISA) and heterogeneous GISA isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12917254" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pharmacodynamic profile of daptomycin against Enterococcus species and methicillin-resistant Staphylococcus aureus in a murine thigh infection model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24092854" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : A current perspective on daptomycin for the clinical microbiologist.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17923487" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22608137" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Antimicrobial activity of daptomycin in comparison to glycopeptides and other antimicrobials when tested against numerous species of coagulase-negative Staphylococcus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30617095" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Evolution of Daptomycin Resistance in Coagulase-Negative Staphylococci Involves Mutations of the Essential Two-Component Regulator WalKR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30617095" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Evolution of Daptomycin Resistance in Coagulase-Negative Staphylococci Involves Mutations of the Essential Two-Component Regulator WalKR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30617095" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Evolution of Daptomycin Resistance in Coagulase-Negative Staphylococci Involves Mutations of the Essential Two-Component Regulator WalKR.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32353412" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Daptomycin in the treatment of enterococcal bloodstream infections and endocarditis: a EUCAST position paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31092593" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The New, New Daptomycin Breakpoint for Enterococcus spp.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32016379" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Occurrence of cross-resistance andβ-lactam seesaw effect in glycopeptide-, lipopeptide- and lipoglycopeptide-resistant MRSA correlates with membrane phosphatidylglycerol levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21393156" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Daptomycin non-susceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26143590" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Insights and clinical perspectives of daptomycin resistance in Staphylococcus aureus: A review of the available evidence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23215859" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Mechanisms of daptomycin resistance in Staphylococcus aureus: role of the cell membrane and cell wall.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21899450" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Genetic basis for in vivo daptomycin resistance in enterococci.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31332078" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Environment Shapes the Accessible Daptomycin Resistance Mechanisms in Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23076243" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Intrinsic and acquired resistance mechanisms in enterococcus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31182276" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : MprF-mediated daptomycin resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32999359" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Association of mprF mutations with cross-resistance to daptomycin and vancomycin in methicillin-resistant Staphylococcus aureus (MRSA).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31559654" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Daptomycin-resistant Staphylococcus aureus clinical isolates are poorly sensed by dendritic cells.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30808758" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Antibiotic resistance and host immune evasion in Staphylococcus aureus mediated by a metabolic adaptation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12654665" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005801" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17005801" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Pharmacokinetics and tolerability of daptomycin at doses up to 12 milligrams per kilogram of body weight once daily in healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18316988" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Single-dose pharmacokinetics of daptomycin in children with suspected or proved gram-positive infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25406298" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Daptomycin in paediatrics: current knowledge and the need for future research.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15898002" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15330747" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15388454" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Daptomycin is highly efficacious against penicillin-resistant and penicillin- and quinolone-resistant pneumococci in experimental meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30607829" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Daptomycin Plasma and CSF Levels in Patients with Healthcare-Associated Meningitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21502620" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pharmacokinetics of single-dose daptomycin in patients with suspected or confirmed neurological infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18779352" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : In vivo microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24798278" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Penetration of daptomycin into bone and synovial fluid in joint replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31096056" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Bone penetration of daptomycin in diabetic patients with bacterial foot infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20375031" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Soft tissue and bone penetration abilities of daptomycin in diabetic patients with bacterial foot infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32639465" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Daptomycin for Pediatric Gram-Positive Acute Hematogenous Osteomyelitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31916929" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : In vitro activities of telithromycin against Staphylococcus aureus biofilms compared with azithromycin, clindamycin, vancomycin and daptomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19364845" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30153487" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Acrylic microparticles increase daptomycin intracellular and in vivo anti-biofilm activity against Staphylococcus aureus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22796888" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Activity of linezolid and high-dose daptomycin, alone or in combination, in an in vitro model of Staphylococcus aureus biofilm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29712650" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in In Vitro Static and Dynamic Models.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29744925" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Microcalorimetric detection of staphylococcal biofilm growth on various prosthetic biomaterials after exposure to daptomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32094136" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Impact of Daptomycin Dose Exposure Alone or in Combination withβ-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an In Vitro Biofilm Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29554250" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Unexpected synergistic and antagonistic antibiotic activity against Staphylococcus biofilms.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27297479" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : New Insight into Daptomycin Bioavailability and Localization in Staphylococcus aureus Biofilms by Dynamic Fluorescence Imaging.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19451285" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Daptomycin rapidly penetrates a Staphylococcus epidermidis biofilm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22123684" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Efficacy of daptomycin versus vancomycin in an experimental model of foreign-body and systemic infection caused by biofilm producers and methicillin-resistant Staphylococcus epidermidis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27295353" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effects of vancomycin, daptomycin, and tigecycline on coagulase-negative staphylococcus biofilm and bacterial viability within biofilm: an in vitro biofilm model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14693519" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : In vivo pharmacodynamic activity of daptomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12937016" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Postantibiotic effects of daptomycin against 14 staphylococcal and pneumococcal clinical isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19759041" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Comparative antibacterial effects of daptomycin, vancomycin and teicoplanin studied in an in vitro pharmacokinetic model of infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23361566" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Variability of pharmacokinetic parameters in patients receiving different dosages of daptomycin: is therapeutic drug monitoring necessary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30243587" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Current use of daptomycin and systematic therapeutic drug monitoring: Clinical experience in a tertiary care institution.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30188976" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31284042" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Pharmacodynamics of daptomycin in combination with other antibiotics for the treatment of enterococcal bacteraemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32383061" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Antimicrobial therapeutic drug monitoring in critically ill adult patients: a Position Paper.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26384039" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Therapeutic Drug Monitoring of Daptomycin: A Retrospective Monocentric Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31836287" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Observational study to determine the optimal dose of daptomycin based on pharmacokinetic/pharmacodynamic analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27509826" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Staphylococcus aureus osteo-articular infection: usefulness of the determination of daptomycin serum concentration to explain a treatment failure.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28575511" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Population pharmacokinetics and dosing considerations for the use of daptomycin in adult patients with haematological malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30086083" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Simple LC-MS/MS Methods Using Core-Shell Octadecylsilyl Microparticulate for the Quantitation of Total and Free Daptomycin in Human Plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30279024" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Daptomycin for the treatment of Staphylococcus aureus infections complicated by septic pulmonary emboli.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26108157" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26168988" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Daptomycin for the Treatment of Infective Endocarditis: Results from European Cubicin(®) Outcomes Registry and Experience (EU-CORE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26976128" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26563898" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Daptomycin for the treatment of osteomyelitis and orthopaedic device infections: real-world clinical experience from a European registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29879481" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : High-dose daptomycin in patients with infective endocarditis or sternal wound infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26888539" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Daptomycin&gt;6 mg/kg/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference center.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29187163" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Daptomycin treatment in patients with resistant staphylococcal periprosthetic joint infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22908174" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Randomized controlled trial of the safety and efficacy of Daptomycin versus standard-of-care therapy for management of patients with osteomyelitis associated with prosthetic devices undergoing two-stage revision arthroplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19153034" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Effectiveness of low-dose daptomycin in the treatment of vancomycin-resistant enterococcal urinary tract infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27343082" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : A retrospective study of outcomes of device-associated osteomyelitis treated with daptomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21208910" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23774437" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Multicenter study of high-dose daptomycin for treatment of enterococcal infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26168986" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Real-World Treatment of Enterococcal Infections with Daptomycin: Insights from a Large European Registry (EU-CORE).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26610384" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin(®) Outcomes Registry and Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28011602" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Comparative Effectiveness and Safety of Standard-, Medium-, and High-Dose Daptomycin Strategies for the Treatment of Vancomycin-Resistant Enterococcal Bacteremia Among Veterans Affairs Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24259698" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Daptomycin dosing strategies in patients receiving thrice-weekly intermittent hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21393490" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Pharmacokinetics and pharmacodynamics of intravenous daptomycin during continuous ambulatory peritoneal dialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20890189" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Daptomycin pharmacokinetics in critically ill patients receiving continuous venovenous hemodialysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23182044" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Daptomycin serum levels in critical patients undergoing continuous renal replacement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32083673" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Population pharmacokinetics and dosing considerations of daptomycin in critically ill patients undergoing continuous renal replacement therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23712701" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Safety and effectiveness of daptomycin across a hospitalized obese population: results of a multicenter investigation in the southeastern United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30728962" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Daptomycin dosing in obese patients: analysis of the use of adjusted body weight versus actual body weight.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24145531" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Daptomycin dosing based on ideal body weight versus actual body weight: comparison of clinical outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19237886" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Pharmacokinetic issues for antibiotics in the critically ill patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27412121" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23891432" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Population pharmacokinetics of daptomycin in patients affected by severe Gram-positive infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24046298" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Considerations for higher doses of daptomycin in critically ill patients with methicillin-resistant Staphylococcus aureus bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29572042" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Population pharmacokinetics of daptomycin in critically ill patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30295740" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Population pharmacokinetics of daptomycin in critically ill patients with various degrees of renal impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24586060" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Successful treatment of infective panniculitis with daptomycin in a pregnant, morbidly obese patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18349306" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Successful treatment of vancomycin-resistant Enterococcus faecium pyelonephritis with daptomycin during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20197474" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Use of daptomycin in a pregnant patient with Staphylococcus aureus endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19249952" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Extremely low excretion of daptomycin into breast milk of a nursing mother with methicillin-resistant Staphylococcus aureus pelvic inflammatory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29172024" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Daptomycin excretion into human milk.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30953921" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Determination of daptomycin in human plasma and breast milk by UPLC/MS-MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30953921" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Determination of daptomycin in human plasma and breast milk by UPLC/MS-MS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32839217" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Adjuvantβ-Lactam Therapy Combined with Vancomycin or Daptomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia: a Systematic Review and Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33143290" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : The Evolving Reduction of Vancomycin and Daptomycin Susceptibility in MRSA-Salvaging the Gold Standards with Combination Therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32514561" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Mechanistic Insights Into the Differential Efficacy of Daptomycin Plusβ-Lactam Combinations Against Daptomycin-Resistant Enterococcus faecium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30962347" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis/oralis in an Ex Vivo Simulated Endocarditis Vegetation Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32964392" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : In Vitro Antimicrobial Activity of Fosfomycin, Vancomycin and Daptomycin Alone, and in Combination, Against Linezolid-Resistant Enterococcus faecalis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32725216" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Daptomycin Plus Fosfomycin Versus Daptomycin Alone for Methicillin-resistant Staphylococcus aureus Bacteremia and Endocarditis: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31060599" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : A study on combination of daptomycin with selected antimicrobial agents: in vitro synergistic effect of MIC value of 1 mg/L against MRSA strains.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32853336" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Cloxacillin or fosfomycin plus daptomycin combinations are more active than cloxacillin monotherapy or combined with gentamicin against MSSA in a rabbit model of experimental endocarditis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27431211" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23845504" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Daptomycin: the role of high-dose and combination therapy for Gram-positive infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16455939" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16455939" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Treatment failure resulting from resistance of Staphylococcus aureus to daptomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23325425" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Neutropenia associated with prolonged daptomycin use.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15227611" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29668884" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Effect of Statin Coadministration on the Risk of Daptomycin-Associated Myopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16410267" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Rhabdomyolysis and acute renal failure in a patient treated with daptomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16705566" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Rhabdomyolysis during therapy with daptomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18662172" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19222623" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23394685" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Safety of daptomycin in patients completing more than 14 days of therapy: results from the Cubicin®Outcomes Registry and experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29559785" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Safety of high-dose daptomycin in patients with severe renal impairment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33016513" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Safety outcomes with high-dose daptomycin in patients with acute kidney injury and/or end-stage renal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30689699" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Musculoskeletal toxicities in patients receiving concomitant statin and daptomycin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25245515" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Effect of Concomitant 3-Hydroxy-3-Methyl-Glutaryl-CoA Reductase Inhibitor Therapy on Creatine Phosphokinase Levels and Mortality Among Patients Receiving Daptomycin: Retrospective Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24321853" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Evaluation of impact of statin use on development of CPK elevation during daptomycin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22160888" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Safety analysis of high dose (&gt;6 mg/kg/day) daptomycin in patients with concomitant statin therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31723571" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : A Retrospective Multisite Case-Control Series of Concomitant Use of Daptomycin and Statins and the Effect on Creatine Phosphokinase.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25022580" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Musculoskeletal safety outcomes of patients receiving daptomycin with HMG-CoA reductase inhibitors.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17548489" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Influence of morbid obesity on the single-dose pharmacokinetics of daptomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15601805" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : The pharmacokinetics of daptomycin in moderately obese, morbidly obese, and matched nonobese subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11036005" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Once-daily dosing in dogs optimizes daptomycin safety.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15535984" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15367725" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Muscle pain associated with daptomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15743894" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Severe myopathy and possible hepatotoxicity related to daptomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29369189" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Drug-induced eosinophilic pneumonia: A review of 196 case reports.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36447615" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Seventeen Cases of Daptomycin-Induced Eosinophilic Pneumonia in a Cohort of Patients Treated for Bone and Joint Infections: Proposal for a New Algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33923382" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Risk Factors of Daptomycin-Induced Eosinophilic Pneumonia in a Population with Osteoarticular Infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28003110" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Eosinophilic pneumonia caused by daptomycin: Six cases from two institutions and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27999664" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Daptomycin-induced eosinophilic pneumonia - a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27999664" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Daptomycin-induced eosinophilic pneumonia - a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27999664" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Daptomycin-induced eosinophilic pneumonia - a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17207858" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Eosinophilic pneumonia induced by daptomycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Acute respiratory failure due to daptomycin induced eosinophilic pneumonia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35308486" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Eosinophilic Syndromes Associated With Daptomycin Use: Re-exposure Hypersensitivity Pneumonitis and Prior Peripheral Eosinophilia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20121418" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Two cases of daptomycin-induced eosinophilic pneumonia and chronic pneumonitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18180613" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Interaction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time/International Normalized Ratio results.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35262686" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Association Between Statin Use and Daptomycin-related Musculoskeletal Adverse Events: A Mixed Approach Combining a Meta-analysis and a Disproportionality Analysis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
